Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study.
Saved in:
| Title: | Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. |
|---|---|
| Authors: | Greil R; IIIrd Medical Department Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg, Salzburg, Austria. r.greil@salk.at., Tedeschi A; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy., Moreno C; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain., Anz B; Department of Medical Oncology, Tennessee Oncology, Chattanooga, TN, USA., Larratt L; Department of Clinical Hematology, University of Alberta Hospital, Edmonton, Alberta, Canada., Simkovic M; Department of Internal Medicine - Hematology, University Hospital and Medical School Hradec Králové, Hradec Králové, Czech Republic., Gill D; Department of Clinical Hematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Gribben JG; Centre for Haemato-Oncology, Queen Mary University of London, Barts Cancer Institute, London, UK., Flinn IW; Center for Blood Cancers, Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA., Wang Z; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Cheung LWK; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Nguyen AN; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Zhou C; Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Styles L; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA., Demirkan F; Department of Hematology, Dokuz Eylül University, Izmir, Turkey. |
| Source: | Annals of hematology [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1733-1742. Date of Electronic Publication: 2021 May 20. |
| Publication Type: | Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34018029 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Greil+R%22">Greil R</searchLink>; IIIrd Medical Department Paracelsus Medical University, Salzburg Cancer Research Institute-CCCIT, Cancer Cluster Salzburg, Salzburg, Austria. r.greil@salk.at.<br /><searchLink fieldCode="AU" term="%22Tedeschi+A%22">Tedeschi A</searchLink>; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.<br /><searchLink fieldCode="AU" term="%22Moreno+C%22">Moreno C</searchLink>; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Anz+B%22">Anz B</searchLink>; Department of Medical Oncology, Tennessee Oncology, Chattanooga, TN, USA.<br /><searchLink fieldCode="AU" term="%22Larratt+L%22">Larratt L</searchLink>; Department of Clinical Hematology, University of Alberta Hospital, Edmonton, Alberta, Canada.<br /><searchLink fieldCode="AU" term="%22Simkovic+M%22">Simkovic M</searchLink>; Department of Internal Medicine - Hematology, University Hospital and Medical School Hradec Králové, Hradec Králové, Czech Republic.<br /><searchLink fieldCode="AU" term="%22Gill+D%22">Gill D</searchLink>; Department of Clinical Hematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.<br /><searchLink fieldCode="AU" term="%22Gribben+JG%22">Gribben JG</searchLink>; Centre for Haemato-Oncology, Queen Mary University of London, Barts Cancer Institute, London, UK.<br /><searchLink fieldCode="AU" term="%22Flinn+IW%22">Flinn IW</searchLink>; Center for Blood Cancers, Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Cheung+LWK%22">Cheung LWK</searchLink>; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Nguyen+AN%22">Nguyen AN</searchLink>; Translational Medicine, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zhou+C%22">Zhou C</searchLink>; Biostatistics, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Styles+L%22">Styles L</searchLink>; Clinical Science, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.<br /><searchLink fieldCode="AU" term="%22Demirkan+F%22">Demirkan F</searchLink>; Department of Hematology, Dokuz Eylül University, Izmir, Turkey. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229107334%22">Annals of hematology</searchLink> [Ann Hematol] 2021 Jul; Vol. 100 (7), pp. 1733-1742. <i>Date of Electronic Publication: </i>2021 May 20. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>9107334 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0584 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209395555%22">09395555 </searchLink><i>NLM ISO Abbreviation: </i>Ann Hematol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34018029 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s00277-021-04536-6 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1733 Titles: – TitleFull: Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Greil R – PersonEntity: Name: NameFull: Tedeschi A – PersonEntity: Name: NameFull: Moreno C – PersonEntity: Name: NameFull: Anz B – PersonEntity: Name: NameFull: Larratt L – PersonEntity: Name: NameFull: Simkovic M – PersonEntity: Name: NameFull: Gill D – PersonEntity: Name: NameFull: Gribben JG – PersonEntity: Name: NameFull: Flinn IW – PersonEntity: Name: NameFull: Wang Z – PersonEntity: Name: NameFull: Cheung LWK – PersonEntity: Name: NameFull: Nguyen AN – PersonEntity: Name: NameFull: Zhou C – PersonEntity: Name: NameFull: Styles L – PersonEntity: Name: NameFull: Demirkan F IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2021 Jul Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1432-0584 Numbering: – Type: volume Value: 100 – Type: issue Value: 7 Titles: – TitleFull: Annals of hematology Type: main |
| ResultId | 1 |
